Seqens Seqens

X
[{"orgOrder":0,"company":"Nurx","sponsor":"TherapeuticsMD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Nurx Expand Access to ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Nurx

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require a medical procedure.

            Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TherapeuticsMD

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY